Hatteras Venture Partners, a venture capital firm based in Research Triangle Park, N.C., named Sir Andrew Witty as a Venture Partner.
Mr. Witty will primarily focus on the strategic positioning of Hatteras and its portfolio companies in the global health care industry. In addition, he will provide leadership counsel to Hatteras’ portfolio companies.
Mr. Witty is also Chancellor of the University of Nottingham in England and serves on the boards of UnitedHealth Group and G1 Therapeutics, Inc. He was Chief Executive Officer of GlaxoSmithKline, plc (GSK) from 2008 until he retired in 2017.
Mr. Witty joined GSK in 1985 and served in various senior roles in the UK, the U.S., South Africa and Singapore.
Led by Clay B. Thorp and Bob Ingram, Hatteras Venture Partners is a venture capital firm focused on seed and early stage opportunities in biopharmaceuticals, medical devices, diagnostics, healthcare IT and related opportunities in human medicine.
The firm has approximately $450m under management in five venture capital funds.